Recently, it was suggested that the IM resistance in CML cells should be handled through the combined treatment of BCR–ABL kinase inhibitor with histone deacetylase (HDAC) inhibitors.4–6. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.